{"id":"https://openalex.org/W1982955426","doi":"https://doi.org/10.1016/j.vaccine.2015.01.070","title":"Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies","display_name":"Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies","alternate_titles":[],"publication_year":2015,"publication_date":"2015-02-07","ids":{"openalex":"https://openalex.org/W1982955426","doi":"https://doi.org/10.1016/j.vaccine.2015.01.070","mag":"1982955426","pmid":"https://pubmed.ncbi.nlm.nih.gov/25659276"},"language":"en","primary_location":{"id":"doi:10.1016/j.vaccine.2015.01.070","doi":"https://doi.org/10.1016/j.vaccine.2015.01.070","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.vaccine.2015.01.070","pdf_url":null,"source":{"id":"https://openalex.org/S27359860","display_name":"Vaccine","issn_l":"0264-410X","issn":["0264-410X","1873-2518"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-200","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1982955426"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069050805","display_name":"Anna Roos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anna Roos","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019909206","display_name":"Ramon Roozendaal","orcid":"https://orcid.org/0000-0002-4084-4801","observed_orcids":["https://orcid.org/0000-0002-4084-4801"]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Ramon Roozendaal","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands. Electronic address: RRoozend@its.jnj.com","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands. Electronic address: RRoozend@its.jnj.com","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033024990","display_name":"Theeuwsen Jessica","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jessica Theeuwsen","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000535089","display_name":"Sarra Riahi","orcid":"https://orcid.org/0009-0004-0979-0368","observed_orcids":["https://orcid.org/0009-0004-0979-0368"]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sarra Riahi","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060731802","display_name":"Joost Vaneman","orcid":"https://orcid.org/0000-0003-3846-2289","observed_orcids":["https://orcid.org/0000-0003-3846-2289"]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joost Vaneman","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040466825","display_name":"Jeroen T. B. M. Tolboom","orcid":"https://orcid.org/0000-0001-8512-7382","observed_orcids":["https://orcid.org/0000-0001-8512-7382"]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jeroen Tolboom","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012466498","display_name":"Liesbeth Dekking","orcid":"https://orcid.org/0000-0002-3762-834X","observed_orcids":["https://orcid.org/0000-0002-3762-834X"]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Liesbeth Dekking","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Infectious Diseases and Vaccines Therapeutic area, Janssen Research and Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027248747","display_name":"Wouter Koudstaal","orcid":"https://orcid.org/0000-0001-9845-9036","observed_orcids":["https://orcid.org/0000-0001-9845-9036"]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Wouter Koudstaal","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109872740","display_name":"Jaap Goudsmit","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jaap Goudsmit","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Janssen Prevention Center, Center of Excellence within Janssen Research & Development, A Division of Janssen Pharmaceutica, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056910334","display_name":"Katarina Rado\u0161evi\u0107","orcid":"https://orcid.org/0000-0002-6769-8402","observed_orcids":["https://orcid.org/0000-0002-6769-8402"]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]},{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]},{"id":"https://openalex.org/I4210157709","display_name":"Johnson & Johnson (Netherlands)","ror":"https://ror.org/04vkhtf23","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210157709"]}],"countries":["FR","NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Katarina Rado\u0161evi\u0107","raw_affiliation_strings":["Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Sanofi, Global Biotherapeutics, Vitry-sur-Seine, France","Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","Sanofi, Global Biotherapeutics, Vitry-sur-Seine, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands; Sanofi, Global Biotherapeutics, Vitry-sur-Seine, France","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Crucell Holland B.V., Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"]},{"raw_affiliation_string":"Sanofi, Global Biotherapeutics, Vitry-sur-Seine, France","institution_ids":["https://openalex.org/I3018075036"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5019909206"],"corresponding_institution_ids":["https://openalex.org/I4210154236","https://openalex.org/I4210157709"],"apc_list":{"value":3620,"currency":"USD","value_usd":3620},"apc_paid":null,"fwci":1.859,"has_fulltext":false,"cited_by_count":18,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.83076439,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"33","issue":"14","first_page":"1739","last_page":"1747"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10167","display_name":"Influenza Virus Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10167","display_name":"Influenza Virus Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12576","display_name":"vaccines and immunoinformatics approaches","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11135","display_name":"Virology and Viral Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/h5n1-avian-influenza","display_name":"H5N1 avian influenza","score":0.8700000047683716},{"id":"https://openalex.org/keywords/seasonal-influenza-vaccine","display_name":"seasonal influenza vaccine","score":0.8429999947547913},{"id":"https://openalex.org/keywords/cross-reactive-antibodies","display_name":"cross-reactive antibodies","score":0.8169999718666077},{"id":"https://openalex.org/keywords/non-neutralizing-antibodies","display_name":"non-neutralizing antibodies","score":0.8399999737739563},{"id":"https://openalex.org/keywords/heterosubtypic-protection","display_name":"heterosubtypic protection","score":0.8820000290870667},{"id":"https://openalex.org/keywords/hemagglutinin-epitope","display_name":"hemagglutinin epitope","score":0.7269999980926514},{"id":"https://openalex.org/keywords/passive-transfer-of-immunity","display_name":"passive transfer","score":0.49900001287460327},{"id":"https://openalex.org/keywords/humoral-immunity","display_name":"humoral immunity","score":0.7870000004768372},{"id":"https://openalex.org/keywords/trivalent-influenza-vaccine","display_name":"trivalent influenza vaccine","score":0.5759999752044678}],"concepts":[{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.7376497387886047},{"id":"https://openalex.org/C519248777","wikidata":"https://www.wikidata.org/wiki/Q160122","display_name":"Influenza A virus subtype H5N1","level":3,"score":0.63740074634552},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5963201522827148},{"id":"https://openalex.org/C182072434","wikidata":"https://www.wikidata.org/wiki/Q3985103","display_name":"Hemagglutination assay","level":4,"score":0.5937813520431519},{"id":"https://openalex.org/C2780689484","wikidata":"https://www.wikidata.org/wiki/Q383260","display_name":"Influenza vaccine","level":3,"score":0.5823298692703247},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4868716299533844},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.48358267545700073},{"id":"https://openalex.org/C2777546802","wikidata":"https://www.wikidata.org/wiki/Q834390","display_name":"Influenza A virus","level":3,"score":0.4834771752357483},{"id":"https://openalex.org/C22070199","wikidata":"https://www.wikidata.org/wiki/Q192995","display_name":"Vaccination","level":2,"score":0.46170952916145325},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.44814085960388184},{"id":"https://openalex.org/C2780801004","wikidata":"https://www.wikidata.org/wiki/Q1415366","display_name":"Immunization","level":3,"score":0.434764564037323},{"id":"https://openalex.org/C133239900","wikidata":"https://www.wikidata.org/wiki/Q2043512","display_name":"Live attenuated influenza vaccine","level":4,"score":0.4235593378543854},{"id":"https://openalex.org/C32611913","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Titer","level":3,"score":0.3873560130596161},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.38733744621276855},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.35440778732299805}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007115","descriptor_name":"Immunization Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007252","descriptor_name":"Influenza Vaccines","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009976","descriptor_name":"Orthomyxoviridae Infections","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D009976","descriptor_name":"Orthomyxoviridae Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":true},{"descriptor_ui":"D012621","descriptor_name":"Seasons","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053124","descriptor_name":"Influenza A Virus, H5N1 Subtype","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D056738","descriptor_name":"Cross Protection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.vaccine.2015.01.070","doi":"https://doi.org/10.1016/j.vaccine.2015.01.070","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.vaccine.2015.01.070","pdf_url":null,"source":{"id":"https://openalex.org/S27359860","display_name":"Vaccine","issn_l":"0264-410X","issn":["0264-410X","1873-2518"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-200","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"journal-article"},{"id":"pmid:25659276","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25659276","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/f530bab3-55ac-40dc-a1d6-84cdafcffffa","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/f530bab3-55ac-40dc-a1d6-84cdafcffffa","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Roos, A, Roozendaal, R, Theeuwsen, J, Riahi, S, Vaneman, J, Tolboom, J, Dekking, L, Koudstaal, W, Goudsmit, J & Rado\u0161evi\u0107, K 2015, 'Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies', Vaccine, vol. 33, no. 14, pp. 1739-1747. https://doi.org/10.1016/j.vaccine.2015.01.070","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/7c3ed7d0-92c0-41b1-bbea-6ac1be1228df","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/protection-against-h5n1-by-multiple-immunizations-with-seasonal-influenza-vaccine-in-mice-is-correlated-with-h5-crossreactive-antibodies(7c3ed7d0-92c0-41b1-bbea-6ac1be1228df).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Vaccine, 33(14), 1739 - 1747. Elsevier BV","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W1693145019","https://openalex.org/W1966676064","https://openalex.org/W1984416131","https://openalex.org/W1989368177","https://openalex.org/W1994559670","https://openalex.org/W1994941526","https://openalex.org/W2001089308","https://openalex.org/W2002632348","https://openalex.org/W2006010216","https://openalex.org/W2012171571","https://openalex.org/W2013574284","https://openalex.org/W2026171677","https://openalex.org/W2028189879","https://openalex.org/W2029220396","https://openalex.org/W2030094974","https://openalex.org/W2032059503","https://openalex.org/W2034314076","https://openalex.org/W2036182565","https://openalex.org/W2037164614","https://openalex.org/W2038849360","https://openalex.org/W2041319603","https://openalex.org/W2049914644","https://openalex.org/W2053109557","https://openalex.org/W2075307701","https://openalex.org/W2075496425","https://openalex.org/W2076787697","https://openalex.org/W2083048250","https://openalex.org/W2084959328","https://openalex.org/W2091193271","https://openalex.org/W2102335249","https://openalex.org/W2107587363","https://openalex.org/W2108424600","https://openalex.org/W2114581239","https://openalex.org/W2116630939","https://openalex.org/W2127840828","https://openalex.org/W2139738904","https://openalex.org/W2147233754","https://openalex.org/W2152617913","https://openalex.org/W2160881014","https://openalex.org/W2161738112","https://openalex.org/W2163135112","https://openalex.org/W2164807254","https://openalex.org/W2168274941","https://openalex.org/W2318325499","https://openalex.org/W2339080478"],"related_works":["https://openalex.org/W2049914644","https://openalex.org/W1966676064","https://openalex.org/W2213649682","https://openalex.org/W2091193271","https://openalex.org/W2151881550","https://openalex.org/W2588119901","https://openalex.org/W2116630939","https://openalex.org/W2040635697","https://openalex.org/W2079945972"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1982955426","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
